Jul 2nd, 2020 - Head and neck cancers account for approximately 4% of all cancers in the United States1 and are the eighth most common cancer affecting men in the United States.2 The diagnosis of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) carries a poor prognosis, with an overall survival (OS) of approximately 1 year.
May 29th, 2020 - The final results of the randomized phase II ECOG-ACRIN E3311 trial were presented by Robert L. Ferris, MD, PhD, and colleagues during the ASCO20 Virtual Scientific Program (Abstract 6500) and in today's Head and Neck Cancer Oral Abstract Session. The trial, conducted in patients undergoing transoral robotic surgery, tested reduced postoperative radiation therapy in patients with human papillom...
May 12th, 2020 - The novel combination of immune checkpoint inhibitors ipilimumab and nivolumab may offer patients with rare gynecologic neoplasms the opportunity for improved outcomes, according to a new study (Abstract 6091) that will be presented during the ASCO20 Virtual Scientific Program.
May 29th, 2020 - Patients with PD-L1-positive relapsed/refractory head and neck squamous cell carcinoma (HNSCC) who were treated in the KEYNOTE-048 trial experienced and improvement in progression-free survival after subsequent therapy (PFS2) with pembrolizumab (Keytruda) compared with the EXTREME regimen. The PFS2 benefit was consistent in patients who received pembrolizumab alone and those who received added ...
May 30th, 2020 - Three-year follow-up data from the phase 2 EMPOWER-CSCC-1 trial (NCT02760498) demonstrated a clinically meaningful survival and duration of response (DOR) improvement with cemiplimab-rwlc (Libtayo) in patients with advanced cutaneous squamous cell carcinoma (CSCC).
May 30th, 2020 - In the phase 2 trial EMPOWER-CSCC-1 (NCT02760498), up to 3 years of follow-up showed continued response rates, and a clinically meaningful survival and duration of response (DOR) for cemiplimab-rwlc (Libtayo) in patients with advanced cutaneous squamous cell carcinoma (CSCC).
May 29th, 2020 - Treatment with pembrolizumab (Keytruda) improved progression-free survival after subsequent therapy (PFS2) for patients with PD-L1–positive, relapsed/refractory head and neck squamous cell carcinoma (HNSCC) compared with the EXTREME regimen, according to an analysis of the KEYNOTE-048 trial. Pembrolizumab induced better PFS2 outcomes both alone and in combination with chemotherapy.
May 29th, 2020 - Patients treated with pembrolizumab or pembrolizumab plus chemotherapy as first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) had longer progression-free survival (PFS) after the next line of therapy than patients first treated with the EXTREME regimen, according to a study presented during the ASCO20 Virtual Scientific Program (Abstract 6505).
National Cancer Institute
Smoking and drinking alcohol may account for roughly 90% of esophageal squamous cell carcinoma cases in Western countries like the United States. Gastroesophageal reflux/Barrett esophagus is associated with an increased risk of esophageal adenocarcinoma.
National Cancer Institute
Von Hippel-Lindau disease (VHL) is an autosomal dominant disease with a predisposition to multiple neoplasms. Germline pathogenic variants in the VHL gene predispose individuals to specific types of both benign and malignant tumors and cysts in many organ systems.
Lancet (London, England); Hida T, Nokihara H et. al.
May 15th, 2017 - Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability in the single-arm phase 1/2 AF-001JP trial in Japanese patients with ALK-positive non-small-cell lung cancer. Given those promising results, we did a phase 3 trial to directly compare the efficacy and safety of alectinib and crizotinib. J-ALEX was a randomi...
The Lancet. Oncology; Thuss-Patience PC, Shah MA et. al.
Mar 27th, 2017 - Although trastuzumab plus chemotherapy is the standard of care for first-line treatment of HER2-positive advanced gastric cancer, there is no established therapy in the second-line setting. In GATSBY, we examined the efficacy and tolerability of trastuzumab emtansine in patients previously treated for HER2-positive advanced gastric cancer (unresectable, locally advanced, or metastatic gastric c...
Gastroenterology Hadjiliadis D, Khoruts A et. al.
Dec 31st, 2017 - Improved therapy has substantially increased survival of persons with cystic fibrosis (CF). But the risk of colorectal cancer (CRC) in adults with CF is 5-10 times greater compared to the general population, and 25-30 times greater in CF patients after an organ transplantation. To address this risk, the CF Foundation convened a multi-stakeholder task force to develop CRC screening recommendatio...
Lancet (London, England); Powles T, Durán I et. al.
Dec 22nd, 2017 - Few options exist for patients with locally advanced or metastatic urothelial carcinoma after progression with platinum-based chemotherapy. We aimed to assess the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [PD-L1]) versus chemotherapy in this patient population. We conducted this multicentre, open-label, phase 3 randomised controlled trial (IMvigor211) at 217 academic m...
The New England Journal of Medicine; Robson M, Im SA et. al.
Jun 5th, 2017 - Olaparib is an oral poly(adenosine diphosphate-ribose) polymerase inhibitor that has promising antitumor activity in patients with metastatic breast cancer and a germline BRCA mutation. We conducted a randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation and human epidermal growth factor receptor type 2 (...
The New England Journal of Medicine; Masuda N, Lee SJ et. al.
May 31st, 2017 - Patients who have residual invasive carcinoma after the receipt of neoadjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative breast cancer have poor prognoses. The benefit of adjuvant chemotherapy in these patients remains unclear. We randomly assigned 910 patients with HER2-negative residual invasive breast cancer after neoadjuvant chemotherapy (containing anthracyc...
JAMA Singal AG, Gupta S et. al.
Sep 5th, 2017 - Mailed fecal immunochemical test (FIT) outreach is more effective than colonoscopy outreach for increasing 1-time colorectal cancer (CRC) screening, but long-term effectiveness may need repeat testing and timely follow-up for abnormal results. Compare the effectiveness of FIT outreach and colonoscopy outreach to increase completion of the CRC screening process (screening initiation and follow-u...
Journal of Clinical Oncology : Official Journal of the Am... Chlebowski RT, Aragaki AK et. al.
Jun 27th, 2017 - Purpose Earlier Women's Health Initiative Dietary Modification trial findings suggested that a low-fat eating pattern may reduce breast cancers with greater mortality. Therefore, as a primary outcome-related analysis from a randomized prevention trial, we examined the long-term influence of this intervention on deaths as a result of and after breast cancer during 8.5 years (median) of dietary i...
Gastroenterology Park SY, Boushey CJ et. al.
Apr 21st, 2017 - Healthy eating patterns assessed by diet quality indexes (DQIs) have been related to lower risk of colorectal cancer-mostly among whites. We investigated the associations between 4 DQI scores (the Healthy Eating Index 2010 [HEI-2010], the Alternative Healthy Eating Index 2010 [AHEI-2010], the alternate Mediterranean diet score [aMED], and the Dietary Approaches to Stop Hypertension score) and c...
Gastrointestinal Endoscopy; Chen C, Stock C et. al.
Apr 22nd, 2017 - Colonoscopy has been demonstrated to be effective in reducing colorectal cancer (CRC) incidence and mortality and has been widely used for primary CRC screening in Germany and the United States. We performed a population-based analysis to evaluate and compare the public health impact of recent colonoscopy use on CRC deaths among adults aged 55 to 79 years in Germany and the United States from 2...